Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out
A
Andreas Michael Schmitt
(Department of Medical Oncology, University Hospital Basel, Basel, Switzerland)
J
James Larkin
S
Sapna P. Patel
(Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX)
Abstract
This comment discusses the use of PD-L1 as a biomarker to guide treatment decisions for metastatic melanoma.
Article Details
Journal
Journal of Clinical Oncology
Volume / Issue
Vol. 43, Issue 2
Published
January 10, 2025
Pages
122-124
ISSN
0732-183X
Publisher
Lippincott Williams & Wilkins
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
ISSN: 0732-183X Health Sciences
Authors (3)
A
Andreas Michael Schmitt
Department of Medical Oncology, University Hospital Basel, Basel, Switzerland
J
James Larkin
S
Sapna P. Patel
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Related Articles from this Journal
Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer
Ismaela Anna Vascotto, Filippo Antonica et al.
Aug 2026
10.1200/jco-26-00658
Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial
Samer A. Srour, Jad Chahoud et al.
Aug 2026
10.1200/jco-26-00388
Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection
Risako Komata, Kenju Ando et al.
Aug 2026
10.1200/jco-26-00140
Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)
Ghayas C. Issa, Branko Cuglievan et al.
Aug 2026
10.1200/jco-26-01743
Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer
Irbaz Bin Riaz, R. Bryan Rumble et al.
Aug 2026
10.1200/jco-26-01001